GlassScriptPhysician profile
Jianlin Wu
NPI 1265687347
$3,277.57
in general payments reported to CMS, 2019-2025
14 companies · $25.52 in 2025
The $25.52 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,358 · 2020: $275 · 2021: $142 · 2022: $464 · 2023: $642 · 2024: $371 · 2025: $25.52.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,038.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,038.22 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $1,044.18 | 2019-2023 | Vemlidy |
| Astrazeneca Pharmaceuticals LP | $477.17 | 2019-2023 | Breztri |
| Abbvie INC. | $399.38 | 2019-2024 | Creon |
| Glaxosmithkline, LLC. | $271.58 | 2019-2025 | Arexvy, Shingrix |
| Novo Nordisk INC | $250.00 | 2019-2020 | |
| Stryker Corporation | $166.67 | 2023 | Mako |
| Medtronic, INC. | $135.29 | 2022 | |
| Angiodynamics, INC. | $125.00 | 2024 | Nanoknife |
| E.R. Squibb & Sons, L.L.C. | $124.07 | 2019 | |
| Microvention, INC. | $117.07 | 2021 | |
| Nuvasive, INC. | $90.91 | 2022 | |
| Amgen INC. | $42.06 | 2023 | Evenity, Prolia |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $20.00 | 2023 | Xifaxan, Trulance |
| Alkermes, INC. | $14.19 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jianlin Wu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.